Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Cobenfy--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy.

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.94, denoting a +2.7% move from the preceding trading day.

Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.

Bristol-Myers Squibb's new Opdivo Qvantig injectable delivery is expected to secure additional 20Y patent protection, with their efforts to drive physician adoption before 2028 likely to temper top-line erosion risks. Their portfolio renewal is progressing well, with the Growth Portfolio already comprising 59.2% of its FQ4'25 revenues (+7.2 points YoY/+55.9 from FY2021 levels of 3.3%). BMY's robust cash flows and manageable net debt levels support their secure dividend investment thesis, even amid increased R&D and M&A activities.

Both companies have distributions boasting above-average yields. One is even a Dividend King.

Bristol Myers has historically been a good and safe dividend stock to own. A strong track record, however, doesn't guarantee future payments will be safe.

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.